We herein report an innovative antisense approach based on Peptide Nucleic Acids (PNAs) to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.